Gabster43213 said:

---

WestTexAg,

10-Q is widely expected to be out this week followed, certainly, by PR which has probably been shelved until last week's completion of 10-K and this week's expected release of 10-Q. If PR reports recruitment of patients for Harvard study and some good news on Texas study, I would not be surprised if we are back to 10 cents again.

---

Ulrich said:

---

The trick, I have found, is to wait for all of you to ride a stock down, then step on board. I didn't spend much on OBMP but my cost basis is only .02.

---

AgShaun00 said:

---

i am about to buyin on the big drop

---

Chief 12 said:

---

AgShaun00 said:

---

i am about to buyin on the big drop

---

BUY THE DIP

---

Quote:

---

On Thursday, we sent you an alert to buy drug developer Nektar Therapeutics (Nasdaq: NKTR) before it released its latest data at the American Society of Clinical Oncology ("ASCO") conference in Chicago.

I'm at ASCO right now and I've seen Nektar's data... It's great. The same patients on its drug keep getting better.
See, every patient in Nektar's trial is tracked on a "waterfall graph."
For any given patient, the best outcome you'd hope to see is a fall in the target tumor size by 100%. And keep in mind that these trials are still running... So as more patients have their tumors shrink, each line keeps falling.
What this means is that over time, people's immune systems are fighting their cancer and clearing it. That's exactly what you'd want to see in an immunotherapy trial: a robust and durable response.
But something about Nektar's data has stymied Wall Street which is why the stock is in free fall today, down about 40% as I write this.
Nektar added a new goal to its waterfall graph, which is becoming totally cancer-free. It's this new, higher standard that makes Nektar's data hard to compare with the historical immunotherapy data from its Big Pharma partner, Bristol-Myers Squibb (BMY).
And yet, that's what all of us would dream about if we or our loved ones were fighting cancer...
You can see this from Nektar's Phase I data, which was just updated for ASCO.

Notice that these were the same 11 end-stage cancer patients with their progress measured at two points in time...

• In November, three patients had their tumors shrink by 80%, and two cleared all of it.
• And then last week, the data show us that seven out of these 11 patients had 80% shrinkage, and three cleared everything.

Ask anyone with stage IV cancer that had spread throughout their bodies if they'd like these odds.
Note, though, this trial still isn't over. And we expect to see more positive responses over time...
That's because all the rest of Nektar's data shows continual improvement, too.
For example, take its lung data. There are only five people in this part of the Phase I trial, so it's hard to draw conclusions from the data. Still, in November one of five had a complete response. But now two out of five have no sign of cancer.
These other three did not have their cancer progress over the last six months. That's also a sort of win. Indeed, "stable disease" is new with immunotherapy. It means a cancer has stopped growing.
However, the open question investors and Wall Street are focused on is whether Nektar's combination data is better than Bristol-Myers' Opdivo drug alone.
To understand this concern, you need to know that a company named Incyte (INCY) failed a Phase III trial in April...
Incyte was developing an IDO-1 drug, epacadostat, to boost Merck's (MRK) immunotherapy drug, Keytruda. But in a head-to-head trial of Keytruda alone compared with Keytruda plus epacadostat, there was no difference. So the company abandoned its clinical trial... and Incyte's share price plunged.
If you are a Nektar shareholder, you're also experiencing this sort of share-price pain today.
But clinically, the difference between Incyte and Nektar is profound...
See, Nektar and the U.S. Food and Drug Administration ("FDA") set a bar for Nektar's trials that's well beyond what's expected from Opdivo alone.
At ASCO, we saw data from three different kinds of cancer so far advanced skin cancer, kidney cancer, and bladder cancer as a first-line therapy, before chemotherapy. All three trials ended in success... skipping over Phase II trials and moving directly to Phase III pivotal trials.
And here's the patient-level data for these trials ending as of late May 2018:

• Fourteen of 28 stage IV skin cancer patients had tumors shrink by more than 30%, while six still have stable disease.
• Twelve of 26 stage IV kidney cancer patients had tumors shrink by more than 30%, while five still have stable disease.
• Six of 10 stage IV bladder cancer patients had tumors shrink by more than 30%, while three still have stable disease.

Again, note that there's still noise in the data, so Phase III trials are needed to show statistical success. Nektar and Bristol-Myers will run these trials, and they could require as many as 750 patients each. So approval for Nektar's cancer drug is not imminent. But now we have an end date to work with.
These trials should start in the third quarter of this year, and they should finish in less than two years after the trials fill up. For investors, this means a 2021 read out to establish statistical success over Opdivo.
So far, every month that Nektar has used this drug combination, its patients keep getting healthier.

---

Ulrich said:

---

I'm rich again! Back up to .038.

---

Gabster43213 said:

---

This week should be an interesting week for OBMP.

---

Ulrich said:

---

Relatively large volume today evidently on block purchases, but I don't see anything really obvious from a news standpoint.

---

OlArmy01 said:

---

Hope no one was riding the NKTR wave

---

Stagecoach said:

---

OlArmy01 said:

---

Hope no one was riding the NKTR wave

---

Have been watching for a buying opportunity. Bought it around 56 when it plummeted.

---